BIORCHESTRA Announces that its Proprietary Compound, BMD-001, Reduces Amyloid-β and Tau Inflammatory Symptoms in Primate Models for Alzheimer's Disease at the RNA Leaders USA Conference
Boston, MA, November 8, 2022, BIORCHESTRA Co., Ltd., a leading RNA therapeutics company whose lead programs focus on neurodegenerative diseases using its proprietary RNA-based drug and drug delivery platforms, announced that their proprietary enzyme has delivered inflammatory reduction response for Alzheimer’s Disease in a groundbreaking study. At the recent RNA Leaders USA Conference in Boston on October 18th, BIORCHESTRA Founder and CEO Dr. Branden Ryu was a featured speaker, where he presented recent efficacy data around their leading compound, BMD-001, derived from studies in non-human primates that demonstrated clearance of both amyloid-β and tau pathological proteins, significant contributors to the symptoms of Alzheimer’s Disease.
Dr. Ryu presented his findings, from work done in collaboration with the National Primate Research Center of the Korea Research Institute of Bioscience and Biotechnology, to the audience of medical and biotechnology researchers and practitioners. Dr. Ryu’s findings demonstrated that BIORCHESTRA’s model could deliver its proprietary intravenous compound, BMD-001, across the blood-brain barrier, which cleared both amyloid-β and tau proteins, markers routinely associated with brain inflammation associated with diseases including Alzheimer’s. His research found that BIORCHESTRA’s Drug Delivery System (BDDS™), using primate testing, repeatedly penetrated the blood-brain barrier, reducing neurodegenerative results. The data further demonstrated the widespread distribution of BMD-001 into the brain’s cortex, bulbar, and cord regions in the primate study.
During his presentation, Dr. Ryu stated, “The encouraging results of this experiment demonstrate that the intravenous injection of our BDDS™ can deliver drugs broadly into the Central Nervous System (CNS) within the brain: the frontal lobe, thalamus, hypothalamus, striatum, and hippocampus, as well as to the spine.” He added, “Our experiment confirmed the biodistribution data of BMD-001 previously established in non-human primate testing, expanding upon the previously proven efficacy of BMD-001 established in smaller animal disease models. This gives us confidence that our brain delivery platform is scalable for humans, offering a potentially groundbreaking treatment model for conditions such as Alzheimer’s Disease and more,” he concluded.
Further to Dr. Ryu’s findings, additional industry leaders presented their research findings, representing leading biopharmaceutical corporations, including Ionis, Alnylam, Sanofi, Bayer, Eli Lilly, Astra Zeneca, Roche, and a handful of emerging biotechnology companies. A particular focus of the recent meeting was the challenge of delivering RNA-based therapeutics to specific organs, particularly the brain.
The RNA Leaders USA Conference focused on research surrounding the scientific, clinical, and commercial development of RNA therapeutics and vaccines. It brought together RNA researchers and experts to discuss updates acoss the RNA landscape.